|Bid||8.75 x 1300|
|Ask||10.55 x 1300|
|Day's Range||8.09 - 10.14|
|52 Week Range||7.95 - 11.20|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
As the mandated quiet period following Applied Therapeutics’s IPO ended, analysts offered glowing estimations of the firm in reports issued Monday.
NEW YORK, June 07, 2019 -- Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated.
Applied Therapeutics Inc. (APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AT-007, a central nervous system (CNS) penetrant Aldose Reductase inhibitor (ARI) in the late stages of preclinical development for the treatment of Galactosemia.
Applied Therapeutics Inc. (APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present data at the European Society for Cardiology 6th World Congress on Acute Heart Failure in Athens, Greece (May 25-May 28, 2019). Two data presentations will be displayed at the Clinical Forum – one as a “Late Breaking Clinical Trial” and the other as a part of the “Basic and Translational Hot Line.” Both presentations highlight AT-001, a novel, potent and selective aldose reductase inhibitor (ARI) in clinical development for Diabetic Cardiomyopathy (DbCM).
President and CEO of Applied Therapeutics Inc (NASDAQ:APLT) Shoshana Shendelman bought 125,000 shares of APLT on 05/16/2019 at an average price of $10 a share.
The U.S. initial public offering market is facing its biggest week since 2015 with at least 15 deals expected to price, including Uber, the biggest IPO since Alibaba in 2014 and biggest U.S. company deal since Facebook in 2012.
If you haven’t found a cure for your fading portfolio in the Street’s hundreds of biotechs, one market newbie wants a shot. The IPO Applied Therapeutics Inc. will issue 4 million shares on the Nasdaq under ...
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Milestone Pharmaceuticals Inc. (MIST) will issue 5 million shares between ...